ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

ASSESSING WELL-BEING AND VIABILITY OF ONDANSETRON, CYCLISATION AND PROCHLORPERAZINE IN PREVENTION OF PONV IN PATIENTS EXPERIENCING LAPAROSCOPIC CHOLECYSTECTOMY

Sarosh Malik, Dr Mahwash Malik, Dr Sonia Sadar

Objective: Postoperative nausea and vomiting is the maximum widely recognized postoperative difficulty in patients undergoing laparoscopic methods, due to the disposition of the pneumoperitoneum during laparoscopic techniques. Various antiemetic drugs have been used to counteract PONV after laparoscopic cholecystectomy. In the current research study, researchers assessed well-being and viability of ondansetron, cyclisation and prochlorperazine in prevention of PONV in cases experiencing laparoscopic cholecystectomy. Methods: Our current research was conducted at Jinnah Hospital, Lahore from October 2017 to September 2018. In the current preliminary, randomized, solo-blind, measured, preliminary study, researchers encompassed 205 patients that experienced elective laparoscopic cholecystectomy and had ASA I or II status. Patients were randomized into three equivalent groups: Group O patients received ondansetron for PONV, Group C patients received cyclisation (55 mg) in addition Set P cases received prochlorperazine. All groups received their PONV medications in unidentifiable 55 ml syringes. All patients were placed under general anesthesia. Metoclopramide remained applied as the rescue antiemetic tranquilizer in all patients. The rate of PONV inside 24 hours, the need for rescue emetic enemas and opposing impacts e.g. brain pain, wooziness and sedation within 6 hours after the medical procedure were the test results initiated. The relative examination was terminated by the Chi-square trial or the carefully varying Fischer's test. The ANOVA test was used to reflect the quantitative factors among three rallies. P < 0.06 remained considered huge. Results: There was no critical distinction between the three gathers with respect to age, sex, ASA status and BMI of the study members. The disease rate was 6 (8.5%) in the ondansetron group, 4 (5.7%) in the cyclisation group and 6 (8.6%) in the prochlorperazine group. Regurgitation occurred in 7 patients (8.7%) in group O, 6 patients (11.9%) in group C and 4 patients (5.7%) in group C (p-esteem 0.68). Emetic rescue enemies were required in 6 patients (8.6%) in group P, 5 patients (7.3%) in group C and 8 patients (11.5%) in set O (p-esteem 0.73). The amount of antagonistic effects, such as migraine, somnolence and sedation, was high in set P associated to set C and set O, but this distinction was not actually significant (p-esteem 0.78, 0.64 and 0.92 separately). Conclusion: Ondansetron, cyclisation and prochlorperazine are similarly real in dropping PONV after laparoscopic cholecystectomy through a satisfactory safety profile. Key words: Ondansetron; Cyclizing; Prochlorperazine; Postoperative nausea and vomiting.

FULL TEXT